26.1 C
New York
Monday, June 8, 2026

Tag: evasion

newssourceFORcompanyinformationcontent1marketreleases

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Crypto Cowboy Roman Storm Goes Down for One Count

Roman Storm, a developer of the crypto tool Tornado Cash, was found guilty in New York of conspiring to operate an unlicensed money transmitting...

Quantifind Joins Forces with OpenSanctions to Deliver the Gold Standard in Sanctions Compliance

PALO ALTO, Calif., Aug. 5, 2025 /CNW/ -- As sanction regimes become more complex and scrutiny intensifies, institutions need more than a list; they...

Quantifind Joins Forces with OpenSanctions to Deliver the Gold Standard in Sanctions Compliance

PALO ALTO, Calif., Aug. 5, 2025 /PRNewswire/ -- As sanction regimes become more complex and scrutiny intensifies, institutions need more than a list; they...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

Newlab and NYC DOT Launch Open Call for AI Startups to Pilot Street-Level Transportation Safety and Infrastructure Solutions

Studio will support startups applying artificial intelligence (AI) to real-world challenges across New York City's transportation network NEW YORK, July 23, 2025 /PRNewswire/ -- Newlab and...

Cytovation to Advance Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling Under International Nonproprietary Name of Getacatetide

Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has approved "getacatetide" as the International Nonproprietary Name (INN) of CY-101.

Tax Evasion Guru Now Drafts the Rulebook—What Could Possibly Go Wrong?

Ken Kies, a lobbyist extraordinaire, has been gifted the keys to the Treasury Department’s tax kingdom. This move is as predictable as a reality...

Daughters of the American Revolution Celebrate National Award Winners at the 134th Continental Congress in Washington, DC

WASHINGTON, July 3, 2025 /PRNewswire/ -- Saturday, June 28 marked the final evening ceremony of the Daughters of the American Revolution (DAR) 134th Continental Congress...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEvasion

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers